Impact of age on the clinical response of patients with CML treated with imatinib
Authors:
Petra Bělohlávková; Jaroslava Voglová; Jakub Radocha; Pavel Žák
Authors‘ workplace:
IV. interní hematologická klinika LF UK a FN Hradec Králové, přednosta doc. MUDr. Pavel Žák, Ph. D.
Published in:
Vnitř Lék 2015; 61(9): 785-791
Category:
Original Contributions
Overview
Introduction:
Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) has significantly changed the survival of patients of all age categories. In our work, we have tried retrospectively to analyze a therapeutic response and toxicity of imatinib according to age of patients (≤ 60 years vs > 60 years). Patients have started treatment with imatinib in 2001–2013 in our department. The duration of treatment was at least 18 months.
Patients and methods:
The whole group contains 103 patients (52 women, 51 men) with a median age at diagnosis of CML 55 years (range 19–88 years). The first group includes 68 the younger patients (31 women, 37 men) with a median age at diagnosis 43 years (range 19–59 years) and the second group 35 the elderly patients (21 women, 14 men) with a median age at diagnosis 70 years (range 61–86 years). Median imatinib dose in both groups was the same – 400 mg per day (range 200–600 mg).
Results:
In the elderly patients we observed higher rates of hematological toxicities (p = 0.0059). After 12 months treatment, a complete cytogenetic response (CCyR) was achieved in 90 % of younger patients and in 74 % of the elderly patients, respectively. Major molecular response (MMR) at 18 months treatment was achieved in 79 % of the younger group and in 63 % of the elderly group.
Conclusion:
The results represent in both groups very good therapeutic response independent of age of patients at the time of CML diagnosis.
Key words:
age – chronic myeloid leukemia – imatinib – therapy
Sources
1. Faber E, Indrák K et al. Chronická myeloidní leukémie. Galén: Praha 2010. ISBN 978–80–7262–680–9.
2. Rohrbacher M, Berger U, Hochhaus A et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL- positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009; 23(3): 602–604.
3. Seiter K. Considerations in the Management of Elderly Patients With Chronic Myeloid Leukemia. Clin Lymph Myeloma Leukemia 2012; 12(1): 12–19.
4. Indrák K, Faber E, Jarošová M. Léčba chronické myeloidní leukemie (CML) v éře imatinibu. Vnitř Lék 2009; 55(Suppl 1): S65-S73.
5. Klamová H. Inhibitory tyrozinových kináz – zásadní změna v prognóze chronické myeloidní leukemie. Vnitř Lék 2013; 59(7): 624–626.
6. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63(4): 789–799.
7. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90(11): 850–858.
8. Baccarani M, Cortes J, Pane F European Leukemia Net. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009; 27(35): 6041–6051.
9. Baccarani M, Deininger MW, Rosti G et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122(6): 872–884.
10. Cortes J, Talpaz M, O’Brien S et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 98(6): 1105–1113.
11. Gugliotta G, Castagnetti F, Palandri F et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 2011; 117(21): 5591–5599.
12. Rosti G, Iacobucci I, Bassi S et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 2007; 92(1): 101–105.
13. Sheehy OM, Irvine AE, Cuthbert RJ et al. Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients. Hematology 2008; 13(3): 133–136.
14. Latagliata R, Ferrero D, Cavazzini F et al. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. Drugs Aging 2013; 30(8): 629–637.
15. Sanchez-Guijo FM, Duran S, Galende J et al. Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study. Leuk Res 2011; 35(9): 1184–1187.
16. Latagliata R, Breccia M, Carmosino I et al. “Real-life” results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res 2010; 34(11): 1472–1475.
17. Latagliata R, Breccia M, Castagnetti F et al. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leuk Res 2011; 35(9): 1164–1169.
18. Lipton JH, le Coutre PD, Wang J et al. Nilotinib in elderly chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: efficacy and safety analysis. Blood (ASH Annual Meeting Abstracts) 2008; 112: 3233.
19. le Coutre PD, Turkina A, Kim DW et al. Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study. Blood (ASH Annual Meeting Abstracts) 2009; 114(22): 3286.
20. Breccia M, Luciano L, Latagliata R et al. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leuk Res 2014; 38(10): 1173–1176.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2015 Issue 9
Most read in this issue
- Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder
- Usefulness of vena cava filters from clinicians view
- Draft of the best medical treatment in patients with low-risk thyroid cancer
- Secondary humoral immunodeficiency in patiens with systemic lupus erythematosus